ASCO 2022 Update
Our coverage of CAR-T at international congresses continues with a look at ASCO 2022 through a series of recently published articles. We hope you enjoy reading them. Race and ethnicity […]
ASCO 2022
Liso-cel in LBCL – PILOT Study
PILOT is a phase II study evaluating lisocabtagene maraleucel as a second-line therapy for large B-cell lymphoma.
Race and ethnicity in CAR-T therapies: Efficacy and Access
Minority ethnic and racial groups are underrepresented in clinical trials leading to a reliance on real-world data for understanding the effects in these groups. Here we report on real-world data presented at ASCO 2022 on this topic.
Emerging CAR-T technologies – ASCO 2022
Current CAR-T therapies come with challenges around manufacturing time, antigen loss, and incidence of adverse events. An emerging crop of therapies aim to overcome these challenges with novel manufacturing processes or mechanisms of action.
CAR-T-ddBCMA in relapsed or refractory multiple myeloma
CAR-T-ddBCMA is a new CAR-T therapy with the potential to overcome immunogenicity challenges faced by other therapies